glp 1 novo nordisk CEO explains why new GLP-1 pill expands access to drug Novo, Lilly weight-loss drugs should

GLP-1 RAs and Peripheral Arterial Disease

Designed to help maintain balanced blood sugar metabolism and daily metabolic function

Thus, expectations for the overall magnitude of effect from a given agent might be modest when treating patients whose baseline A1c is 30 pioglitazone reduced HbA1c levels better than sitagliptin while in individuals with a BMI 90 canagliflozin lowered HbA1c better than sitagliptin while in individuals with an eGFR between 60-90 sitagliptin was more effective (13)

Pemilihan agonis reseptor GLP-1 tertentu tergantung pada berbagai faktor, termasuk preferensi pasien, profil efek samping, dan biaya